Abstract Background Imiquimod is a Toll-like receptor-7 agonist capable of inducing
complete clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We …

Purpose: Imiquimod represents a synthetic local immune response modifier that has
demonstrated efficacy in clearing basal cell carcinoma. Via interaction with Toll-like receptor …

Imiquimod is a topical immune response modifier that binds to Toll‐like receptor‐7 and‐8,
inducing interferon‐α. We treated superficial basal cell carcinomas (BCC) with imiquimod …

Supported by the Office of International Affairs, National Cancer Institute (NCI), the" US-
Japan Workshop on Immunological Biomarkers in Oncology" was held in March 2009. The …

Background Imiquimod is a local immune response modifier that has demonstrated potent
antiviral and antitumor activity. It enhances innate and acquired immune responses via …

Background: Imiquimod, an immune response modifier that is used topically to treat different
types of skin cancer, induces the production of proinflammatory cytokines that stimulate an …

Background Imiquimod is an immune response modifier that acts through toll‐like receptor 7
to induce cytokine production and a subsequent innate and adaptive cell‐mediated immune …

The advent of high-throughput technology challenges the traditional histopathological
classification of cancer, and proposes new taxonomies derived from global transcriptional …

Purpose: Despite lymphocyte infiltration of tumors and the activation of tumor-draining lymph
nodes, malignant tumors are able to “escape” from both innate and adaptive immune …

Imiquimod is a topical toll-like-receptor-7 agonist currently used for treating basal cell
carcinoma. Recently, imiquimod has demonstrated tumor regression in melanoma and …